Please login to the form below

cemiplimab

This page shows the latest cemiplimab news and features for those working in and with pharma, biotech and healthcare.

Regeneron’s Libtayo granted EC approval for recurrent or metastatic cervical cancer

Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) has been approved by the European Commission (EC) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease

Latest news

Regeneron’s Libtayo combination granted FDA approval for non-small-cell lung cancer

Regeneron’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) has been approved by the US Food and Drug Administration (FDA) in combination with platinum-based chemotherapy as a first-line treatment for ... Even with these diverse disease presentations,
Regeneron’s fianlimab/Libtayo combination shows positive results in advanced melanoma treatment

Libtayo (cemiplimab) in advanced melanoma.
Regeneron’s Libtayo shows promising results in phase 2 skin cancer trial

Regeneron has announced positive data from a phase 2 trial for an investigational regimen of PD-1 inhibitor Libtayo (cemiplimab) as a neoadjuvant monotherapy in stage two to four resectable cutaneous
NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC

The National Institute for Health and Care Excellence (NICE) has recommended Sanofi and Regeneron’s Libtayo (cemiplimab) for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC). ... The multicentre, non-randomised
Merck’s Keytruda improves outcomes for metastatic cervical cancer patients

In March, Sanofi and Regeneron revealed positive data for their PD-1 inhibitor Libtayo (cemiplimab) in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.

More from news
Approximately 3 fully matching, plus 30 partially matching documents found.

Latest Intelligence

Regeneron and Bluebird sign $100m cell therapies deal

Regeneron and its long-standing partners Sanofi look set to gain FDA approval for their PD-1 immunotherapy contender, cemiplimab in October, while Bluebird is poised to file its

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

PMHub

Add my company

Springer Nature

Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story: ...
Working together to achieve better patient pathways: Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.: How design can lead improvement within Pharma...

Email:
Password:

Please login to the form below

cemiplimab

Subscribe to our email news alerts

Quick links